A 16-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm2) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-Year Open-Label Treatment Phase.

Trial Profile

A 16-Week, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy of Rivastigmine Patch (10 cm2) on Cognitive Deficits in Patients With Multiple Sclerosis, Followed by a 1-Year Open-Label Treatment Phase.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Apr 2013

At a glance

  • Drugs Rivastigmine (Primary)
  • Indications Cognition disorders
  • Focus Therapeutic Use
  • Acronyms EXCITING
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2012 New source identified and integrated (European Clinical Trials Database;EudraCT2008-007015-32).
    • 23 Feb 2012 Planned end date changed from 1 Mar 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov.
    • 04 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top